The Supreme Court and Biosimilars: What if it All Goes Away?
This article was originally published in RPM Report
After the bruising health care reform debate in Congress, biopharmaceutical companies were comfortably on the periphery of the legal arguments playing out in the Supreme Court. But being peripheral has its disadvantages: if the Court sides with the challengers, it is possible that one of the “peripheral” provisions tossed aside will be the new biosimilars pathway. That would be a disaster for innovator companies.